Mariana Castells
#142,432
Most Influential Person Now
Spanish-American allergist
Mariana Castells's AcademicInfluence.com Rankings
Mariana Castellsphilosophy Degrees
Philosophy
#7485
World Rank
#10706
Historical Rank
Logic
#4529
World Rank
#5838
Historical Rank
Download Badge
Philosophy
Why Is Mariana Castells Influential?
(Suggest an Edit or Addition)According to Wikipedia, Mariana Castells is a Spanish-American allergist who focuses on mast cell diseases, including mastocytosis, mast cell activation syndrome and hereditary alpha tryptasimia. Mastocytosis is a rare disease with limited treatment options. Castells works at Brigham and Women's Hospital in Massachusetts in the Department of Allergy, Rheumatology, and Immunology and at the Dana Farber Cancer Institute. She is also a professor of medicine at Harvard Medical School.
Mariana Castells's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- International Consensus on drug allergy (2014) (711)
- Standards and standardization in mastocytosis: Consensus Statements on Diagnostics, Treatment Recommendations and Response Criteria (2007) (695)
- Drug allergy: an updated practice parameter. (2010) (572)
- Quantitation of histamine, tryptase, and chymase in dispersed human T and TC mast cells. (1987) (498)
- Definitions, Criteria and Global Classification of Mast Cell Disorders with Special Reference to Mast Cell Activation Syndromes: A Consensus Proposal (2011) (479)
- Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. (2008) (460)
- Maintaining Safety with SARS-CoV-2 Vaccines (2020) (297)
- General considerations on rapid desensitization for drug hypersensitivity – a consensus statement (2010) (282)
- Evaluation of human peripheral blood leukocytes for mast cell tryptase. (1987) (276)
- Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. (2016) (258)
- Anaphylaxis During the Perioperative Period (2003) (255)
- Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment. (2009) (244)
- Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes. (2012) (209)
- Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA) (2007) (204)
- Mastocytosis: current concepts in diagnosis and treatment (2002) (202)
- Diagnosis and management of drug hypersensitivity reactions. (2011) (198)
- Diagnosis and management of anaphylaxis in precision medicine (2017) (180)
- Mouse mast cell gp49B1 contains two immunoreceptor tyrosine-based inhibition motifs and suppresses mast cell activation when coligated with the high-affinity Fc receptor for IgE. (1996) (171)
- Hypersensitivity reactions to therapeutic monoclonal antibodies: Phenotypes and endotypes (2018) (150)
- Safety, Costs, and Efficacy of Rapid Drug Desensitizations to Chemotherapy and Monoclonal Antibodies. (2016) (147)
- Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions. (2004) (146)
- Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis (2014) (144)
- Precision medicine in allergic disease—food allergy, drug allergy, and anaphylaxis—PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma and Immunology (2017) (141)
- Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments. (2005) (133)
- Diagnosis and Treatment of Cutaneous Mastocytosis in Children (2011) (132)
- Latex Allergy: An Update (2003) (125)
- Mastocytosis: Mediator-Related Signs and Symptoms (2002) (124)
- Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses. (2005) (122)
- Rapid desensitization for hypersensitivity reactions to medications. (2009) (120)
- Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis. (2008) (116)
- Mast cell activation syndrome: a newly recognized disorder with systemic clinical manifestations. (2011) (114)
- Desensitization for drug allergy (2006) (113)
- A Clinicopathologic Study of 24 Cases of Systemic Mastocytosis Involving the Gastrointestinal Tract and Assessment of Mucosal Mast Cell Density in Irritable Bowel Syndrome and Asymptomatic Patients (2014) (113)
- Rapid IgE desensitization is antigen specific and impairs early and late mast cell responses targeting FcεRI internalization (2011) (112)
- Cloning of the gp49B gene of the immunoglobulin superfamily and demonstration that one of its two products is an early-expressed mast cell surface protein originally described as gp49. (1994) (111)
- Nonsteroidal anti-inflammatory drugs are major causes of drug-induced anaphylaxis. (2014) (107)
- The Mastocytosis Society survey on mast cell disorders: patient experiences and perceptions. (2014) (106)
- Re-visiting Hypersensitivity Reactions to Taxanes: A Comprehensive Review (2015) (103)
- Mast cell mediators in allergic inflammation and mastocytosis. (2006) (101)
- Risk and safety requirements for diagnostic and therapeutic procedures in allergology: World Allergy Organization Statement (2016) (95)
- Ovarian cancer, version 3.2012. (2012) (92)
- Hypersensitivity to biological agents-updated diagnosis, management, and treatment. (2015) (92)
- Practical Guidance for the Evaluation and Management of Drug Hypersensitivity: Specific Drugs. (2020) (85)
- Drug Hypersensitivity and Desensitizations: Mechanisms and New Approaches (2017) (83)
- Exercise-induced Anaphylaxis. (1980) (83)
- Current options in the treatment of mast cell mediator-related symptoms in mastocytosis. (2006) (81)
- Aspirin challenge and desensitization for aspirin-exacerbated respiratory disease: a practice paper. (2007) (79)
- Anaphylaxis in the 21st century: phenotypes, endotypes, and biomarkers (2018) (79)
- Approach to the diagnosis of drug hypersensitivity reactions: similarities and differences between Europe and North America (2017) (78)
- Expanding spectrum of mast cell activation disorders: monoclonal and idiopathic mast cell activation syndromes. (2013) (77)
- Allergy to monoclonal antibodies: cutting-edge desensitization methods for cutting-edge therapies (2012) (77)
- Perioperative Management of Patients with Mastocytosis (2014) (77)
- Hypersensitivity to antineoplastic agents: mechanisms and treatment with rapid desensitization (2012) (76)
- Acetylsalicylic acid and montelukast block mast cell mediator-related symptoms during rapid desensitization. (2009) (74)
- Anesthesia in the patient with multiple drug allergies: are all allergies the same? (2011) (74)
- Carboplatin-, oxaliplatin-, and cisplatin-specific IgE: cross-reactivity and value in the diagnosis of carboplatin and oxaliplatin allergy. (2013) (74)
- Risk stratification and skin testing to guide re-exposure in taxane-induced hypersensitivity reactions. (2016) (73)
- gp49B1-αvβ3 interaction inhibits antigen-induced mast cell activation (2001) (71)
- Penicillin Allergy Testing Should Be Performed Routinely in Patients with Self-Reported Penicillin Allergy. (2017) (71)
- Progestogen Hypersensitivity in 24 Cases: Diagnosis, Management, and Proposed Renaming and Classification. (2016) (66)
- A safe protocol for rapid desensitization in patients with cystic fibrosis and antibiotic hypersensitivity. (2009) (64)
- AllergoOncology – the impact of allergy in oncology: EAACI position paper (2017) (64)
- Antigen-IgE desensitization in signal transducer and activator of transcription 6-deficient mast cells by suboptimal doses of antigen. (2005) (64)
- Penicillin Allergy. (2019) (63)
- Effects of cyclosporin A and FK506 on Fc epsilon receptor type I-initiated increases in cytokine mRNA in mouse bone marrow-derived progenitor mast cells: resistance to FK506 is associated with a deficiency in FK506-binding protein FKBP12. (1992) (63)
- Drug Hypersensitivity and Anaphylaxis in Cancer and Chronic Inflammatory Diseases: The Role of Desensitizations (2017) (62)
- Basophil Activation Test is a Relevant Biomarker of the Outcome of Rapid Desensitization in Platinum Compounds-Allergy. (2017) (61)
- Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. (2018) (59)
- Presentation and Diagnosis of Hypersensitivity to Platinum Drugs (2015) (58)
- Diagnosis and Treatment of Cutaneous Mastocytosis in Children Practical Recommendations (2011) (58)
- Autoimmune progesterone dermatitis: clinical presentation and management with progesterone desensitization for successful in vitro fertilization. (2011) (55)
- Report from the National Institute of Allergy and Infectious Diseases workshop on drug allergy. (2015) (55)
- Mast Cell Activation Syndrome and Mastocytosis: Initial Treatment Options and Long-Term Management. (2019) (55)
- A World Allergy Organization International Survey on Diagnostic Procedures and Therapies in Drug Allergy/Hypersensitivity (2011) (54)
- Mast Cell Restricted Mouse and Human Tryptase·Heparin Complexes Hinder Thrombin-induced Coagulation of Plasma and the Generation of Fibrin by Proteolytically Destroying Fibrinogen* (2012) (54)
- Allergy to white potato. (1986) (53)
- Cephalosporin Allergy: Current Understanding and Future Challenges. (2019) (51)
- Exercise-induced anaphylaxis (EIA) (1999) (51)
- Anaphylaxis after hymenoptera sting: is it venom allergy, a clonal disorder, or both? (2015) (50)
- Mastocytosis: classification, diagnosis, and clinical presentation. (2004) (50)
- Mast cell sarcoma: a rare and potentially under-recognized diagnostic entity with specific therapeutic implications (2013) (46)
- Drug Desensitization in the Management of Hypersensitivity Reactions to Monoclonal Antibodies and Chemotherapy (2014) (45)
- CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disorders. (2006) (44)
- Rapid desensitization for hypersensitivity reactions to chemotherapy agents. (2006) (42)
- Desensitization for hypersensitivity reactions to medications. (2012) (42)
- Hypersensitivity reactions to biologic agents. (2014) (41)
- Diagnoses and Management of Drug Hypersensitivity and Anaphylaxis in Cancer and Chronic Inflammatory Diseases: Reactions to Taxanes and Monoclonal Antibodies (2018) (40)
- Practical Guidelines for the Evaluation and Management of Drug Hypersensitivity: General Concepts. (2020) (40)
- The presence of membrane-bound stem cell factor on highly immature nonmetachromatic mast cells in the peripheral blood of a patient with aggressive systemic mastocytosis. (1996) (40)
- Antibiotic Use After Removal of Penicillin Allergy Label (2018) (39)
- Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal (2021) (39)
- Immunology and Clinical Manifestations of Non-Clonal Mast Cell Activation Syndrome (2013) (39)
- Adverse reactions to drugs and biologics in patients with clonal mast cell disorders: A Work Group Report of the Mast Cells Disorder Committee, American Academy of Allergy, Asthma & Immunology. (2019) (38)
- Anaphylaxis in the Clinical Setting of Obstetric Anesthesia: A Literature Review (2013) (38)
- Taxol reactions. (2002) (38)
- Rapid desensitization for hypersensitivity reactions to chemotherapy agents (2006) (37)
- Outcomes and safety of rapid desensitization for chemotherapy hypersensitivity (2010) (37)
- mRNA COVID-19 vaccine is well tolerated in patients with cutaneous and systemic mastocytosis with mast cell activation symptoms and anaphylaxis (2021) (36)
- Anaphylaxis to chemotherapy and monoclonal antibodies. (2015) (35)
- Anaphylaxis and hypersensitivity reactions (2011) (35)
- Exercise-induced anaphylaxis (1987) (34)
- Rapid subcutaneous desensitization for the management of local and systemic hypersensitivity reactions to etanercept and adalimumab in 12 patients. (2015) (34)
- Desensitizations for Chemotherapy and Monoclonal Antibodies: Indications and Outcomes (2014) (33)
- For the European Network of Drug Allergy and the EAACI interest group on drug hypersensitivity. General considerations on rapid desensitization for drug hypersenitivity - a consensus statement (2010) (33)
- AllergoOncology: ultra-low IgE, a potential novel biomarker in cancer—a Position Paper of the European Academy of Allergy and Clinical Immunology (EAACI) (2020) (33)
- Association of anti-IgA antibodies with adverse reactions to γ-globulin infusion. (2010) (32)
- Severity grading system for acute allergic reactions: a multidisciplinary Delphi study. (2021) (31)
- What can we learn in drug allergy management from World Health Organization's international classifications? (2018) (31)
- Applying lessons learned from nanomedicines to understand rare hypersensitivity reactions to mRNA-based SARS-CoV-2 vaccines (2022) (31)
- NSAID single-drug-induced reactions. (2013) (30)
- Hypersensitivity to antineoplastic agents. (2008) (30)
- Patient Perceptions in Mast Cell Disorders. (2018) (29)
- Patients with positive skin test results to penicillin should not undergo penicillin or amoxicillin challenge. (2015) (28)
- Deficiency of Interleukin-1 Receptor Antagonist (DIRA): Report of the First Indian Patient and a Novel Deletion Affecting IL1RN (2017) (27)
- The gp49A gene has extensive sequence conservation with the gp49B gene and provides gp49A protein, a unique member of a large family of activating and inhibitory receptors of the immunoglobulin superfamily (1999) (27)
- Injection‐site reaction to etanercept: role of skin test in the diagnosis of such reaction and successful desensitization (2011) (27)
- Hypersensitivity reactions to chemotherapy: an EAACI Position Paper (2021) (27)
- COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM) (2021) (26)
- Perioperative Anaphylaxis (2014) (25)
- Positive basophil activation test following anaphylaxis to pertuzumab and successful treatment with rapid desensitization. (2016) (25)
- Perioperative anaphylaxis to cefazolin. (2004) (25)
- Mast cell activation syndrome: Importance of consensus criteria and call for research. (2018) (24)
- Role of Skin Tests in the Diagnosis of Immediate Hypersensitivity Reactions to Taxanes: Results of a Multicenter Study. (2019) (24)
- Controversies in Allergy: Chemotherapy reactions, desensitize or de-label? (2020) (23)
- Drug Desensitization in Oncology: Chemotherapy Agents and Monoclonal Antibodies (2007) (23)
- Anaphylaxis to quinolones in mastocytosis: Hypothesis on the mechanism. (2019) (23)
- Hereditary alpha-tryptasemia in 101 patients with mast cell activation-related symptomatology including anaphylaxis. (2021) (23)
- Generalized bullous eruption after routine vaccination in a child with diffuse cutaneous mastocytosis. (2013) (23)
- Carboplatin-allergic patients undergoing desensitization: prevalence and impact of the BRCA 1/2 mutation. (2017) (22)
- Use and interpretation of acute and baseline tryptase in perioperative hypersensitivity and anaphylaxis. (2021) (22)
- Clinical and laboratory improvement after intravenous immunoglobulin in drug reaction with eosinophilia and systemic symptoms. (2014) (22)
- Persistent, refractory, and biphasic anaphylaxis: a multidisciplinary Delphi study. (2020) (22)
- Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions (2020) (22)
- Desensitization for Drug Hypersensitivity to Chemotherapy and Monoclonal Antibodies. (2017) (21)
- gp49B1-alpha(v)beta3 interaction inhibits antigen-induced mast cell activation. (2001) (20)
- Classification of angioedema by endotypes (2015) (20)
- Perioperative anaphylaxis and the United States perspective. (2011) (20)
- Hypersensitivity Reactions to Platinum Agents and Taxanes (2021) (20)
- Interleukin‐6: A novel biomarker for monoclonal antibody and chemotherapy‐associated hypersensitivity confirms a cytokine release syndrome phenotype‐endotype association (2020) (19)
- Rapid Desensitization to antineoplastic drugs in an outpatient Immunoallergology Clinic: outcomes and risk factors. (2020) (19)
- Rapid Desensitization in Immediate Hypersensitivity Reaction to Drugs (2015) (18)
- Important questions in drug allergy and hypersensitivity: consensus papers from the 2018 AAAAI/WAO international drug allergy symposium (2018) (18)
- Patients with mast cell activation symptoms and elevated baseline serum tryptase have unique bone marrow morphology. (2020) (18)
- Penicillin Allergy Testing, A Key Component of Antibiotic Stewardship. (2016) (18)
- Idiopathic anaphylaxis yardstick: Practical recommendations for clinical practice. (2019) (17)
- Application of precision medicine to the treatment of anaphylaxis (2018) (16)
- Hypersensitivity reactions to biologicals: An EAACI position paper (2021) (16)
- Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review. (2021) (16)
- Laronidase hypersensitivity and desensitization in type I mucopolysaccharidosis: a case report (2014) (16)
- Management of adverse reactions to biologic agents. (2017) (15)
- Rituximab hypersensitivity and desensitization: a personalized approach to treat cancer and connective tissue diseases. (2019) (15)
- Perioperative anaphylaxis in a 44-year-old man. (2007) (14)
- Injection site reaction to adalimumab: Positive skin test and successful rapid desensitisation. (2013) (14)
- Oral Amoxicillin Challenges in Low-Risk Children During a Pediatric Emergency Department Visit. (2020) (14)
- Chemotherapy hypersensitivity reactions in ovarian cancer. (2014) (14)
- Transfer of peanut allergy by a liver allograft. (1998) (14)
- Rapid desensitization to chemotherapy and monoclonal antibodies is effective and safe (2013) (13)
- A New Era for Drug Desensitizations. (2015) (13)
- Diagnosis and Treatment of Drug Hypersensitivity Reactions to Biologicals: Medical Algorithm. (2020) (13)
- Case records of the Massachusetts General Hospital. Case 9-2011. A 37-year-old man with flushing and hypotension. (2011) (13)
- Successful rifampin desensitization in a pediatric patient with latent tuberculosis (2014) (13)
- Should local anesthetic allergy testing be routinely performed during pregnancy? (2003) (13)
- Mast Cells: Molecular And Cell Biology (1998) (13)
- The Mastocytosis Society Survey on Mast Cell Disorders: Part 2-Patient Clinical Experiences and Beyond. (2019) (12)
- Nanoallergen platform for detection of platin drug allergies. (2019) (12)
- Drug hypersensitivity in the fast lane: What clinicians should know about phenotypes, endotypes, and biomarkers. (2020) (12)
- Drug hypersensitivity reactions in Asia: regional issues and challenges (2020) (12)
- Distinct Small Intestine Mast Cell Histologic Changes in Patients With Hereditary Alpha-tryptasemia and Mast Cell Activation Syndrome. (2021) (12)
- Update on mast cells and mast cell precursors and hypersensitivity responses. (1997) (12)
- The Contribution of the Basophil Activation Test to the Diagnosis of Hypersensitivity Reactions to Oxaliplatin (2018) (11)
- Extracutaneous mastocytoma. (2006) (11)
- COVID-19 infection in patients with mast cell disorders including mastocytosis does not impact mast cell activation symptoms (2021) (11)
- Cardiogenic shock and peripheral eosinophilia in a young woman. (2005) (11)
- BAT in the Diagnosis of Drug Allergy: a Novel Tool in Clinical Daily Practice? (2019) (11)
- Anesthetic Management of a Patient with an Allergy to Propylene Glycol and Parabens (2010) (10)
- Mast cell-restricted tetramer-forming tryptases and their beneficial roles in hemostasis and blood coagulation. (2014) (10)
- Global Classification of Mast Cell Activation Disorders An ICD-10-CM-Adjusted Proposal of the ECNM-AIM Consortium. (2022) (10)
- Mast Cell Activation (2016) (10)
- Drug Desensitizations for Chemotherapy: Safety and Efficacy in Preventing Anaphylaxis (2021) (10)
- Idiopathic Anaphylaxis: A Form of Mast Cell Activation Syndrome. (2020) (9)
- Standards and standardization in mastocytosis (2007) (9)
- Soluble FcεRI, IgE, and tryptase as potential biomarkers of rapid desensitizations for platin IgE sensitized cancer patients. (2020) (8)
- Hypersensitivity Reaction and Tolerance Induction to Ethambutol (2013) (8)
- Specific questionnaire detects a high incidence of intra-operative hypersensitivity reactions (2018) (8)
- Penicillin Allergy Testing: A Key Component of Antibiotic Stewardship. (2016) (8)
- One-day ultrarush desensitization for Hymenoptera venom anaphylaxis in patients with and without mast cell disorders with adjuvant omalizumab. (2019) (8)
- HYPERSENSITIVITY REACTIONS AND ANAPHYLAXIS TO CHECKPOINT INHIBITOR-MONOCLONAL ANTIBODIES AND DESENSITIZATION. (2021) (8)
- Drug Allergy: Phenotypes, Endotypes, and Biomarkers. (2017) (7)
- Drug-Induced Paradoxical Vocal Fold Motion. (2018) (7)
- Anaphylaxis and Coronavirus Disease 2019 vaccine: a danger relationship? (2021) (7)
- Common variable immunodeficiency. (2002) (7)
- Fatal anaphylaxis caused by gadolinium due to beta-tryptase-induced hemorragic diathesis. (2017) (7)
- Molecular and Cellular Biology of Rodent Mast Cells. (1992) (7)
- Medical algorithm: Diagnosis and treatment of drug hypersensitivity reactions to biologicals (2020) (7)
- Anaphylaxis knowledge gaps and future research priorities: a consensus report. (2021) (7)
- Diagnostic procedures & practices in drug allergy/hypersensitivity: a survey of 13 Asian countries (2020) (7)
- Diffuse cutaneous mastocytosis with novel somatic KIT mutation K509I and association with tuberous sclerosis (2018) (6)
- Maintaining Safety with SARS-CoV-2 Vaccines. Reply. (2021) (6)
- Sex and allergic diseases. (2019) (6)
- Use of Omalizumab to Achieve Successful Desensitization After Oxaliplatin Anaphylaxis (2012) (6)
- Standards for practical intravenous rapid drug desensitization & delabeling: A WAO committee statement (2022) (6)
- Mast cell activation during suspected perioperative hypersensitivity: a need for paired samples analysis. (2021) (6)
- Non-IgE adverse reactions to biologics. (2020) (6)
- Surface makers for mast cell subtypes: low affinity IgG receptors and gp49 family. (1994) (6)
- Successful desensitization to 6-mercaptopurine in a patient with Crohn's disease (2000) (6)
- Drug allergy in pediatric patients. (2011) (5)
- The Magnification of Health Disparities During the COVID-19 Pandemic (2022) (5)
- Successful desensitization to rosuvastatin in a patient with a history of anaphylaxis to multiple statins. (2013) (5)
- Algorithm to guide re-exposure to penicillin in allergic pregnant women with syphilis: Efficacy and safety☆ (2021) (5)
- Drug allergy: Veni, vidi, vici-come, understand, and delabel, avoid, or desensitize. (2019) (5)
- Added Value Of Skin Testing In Hypersensitivity Reactions To Taxanes (2014) (5)
- PD-L1 Blockade During Allergen Sensitization Inhibits the Synthesis of Specific Antibodies and Decreases Mast Cell Activation in a Murine Model of Active Cutaneous Anaphylaxis (2021) (5)
- Proceedings from the Inaugural American Initiative in Mast Cell Diseases (AIM) Investigator Conference. (2021) (5)
- PIONEER: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients with Indolent or Smoldering Systemic Mastocytosis (SM) With Symptoms Inadequately Controlled by Standard Therapy (2020) (5)
- Mast Cell Disorders Are Associated with Decreased Cerebral Blood Flow And Small Fiber Neuropathy. (2021) (5)
- Blisters, Vaccines, and Mast Cells: A Difficult Case of Diffuse Cutaneous Mastocytosis. (2019) (5)
- Successful administration of omalizumab by desensitization protocol following systemic reactions in 12 patients. (2021) (5)
- Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User´s Guide for Daily Clinical Practice. (2022) (5)
- Skin Testing for Penicillin Allergy: a Review of the Literature (2021) (4)
- Non-Clonal Mast Cell Activation Syndrome (2014) (4)
- Significant Reduction In Combined Symptom And Medication Score Compared With Placebo Following MPL-Adjuvanted uSCIT In Patients With Seasonal Grass Pollen Allergy (2009) (4)
- Mast cells in lung damage of COVID‐19 autopsies: A descriptive study (2022) (4)
- Proposed ECNM-AIM Response Criteria in Advanced Systemic Mastocytosis. (2022) (4)
- 7th Drug hypersensitivity meeting: part two (2016) (4)
- Desensitization to chemotherapeutic agents. (2014) (4)
- Pioneer Part 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib in Indolent Systemic Mastocytosis (2020) (4)
- Race and allergy: Are we that different? (2019) (4)
- Interactive medical case. A rash hypothesis. (2010) (4)
- Refined Treatment Response Criteria for Indolent Systemic Mastocytosis proposed by the ECNM-AIM Consortium. (2022) (4)
- IgE‐mediated hypersensitivity reaction and desensitization to glatiramer acetate in a pediatric patient (2014) (4)
- Case 9-2011 (2011) (3)
- Anaphylaxis: advances and challenges besides allergy. (2019) (3)
- ANAPHYLAXIS AND PREGNANCY: A SYSTEMATIC REVIEW AND CALL FOR PUBLIC HEALTH ACTIONS. (2021) (3)
- Lipid Mediators in Cutaneous and Systemic Mastocytosis and the Impact of 5-LO Inhibition (2011) (3)
- Mastocytosis: Moving the Field to Precision and Personalized Medicine. (2018) (3)
- Update on Desensitization (2019) (3)
- Successful desensitization to 6-mercaptopurine in a patient with Crohn's disease. (2000) (3)
- Rapid Desensitizations for Antibiotic-Induced Hypersensitivity Reactions and Anaphylaxis (2011) (3)
- Novel Roles for Platinum and Taxane Agent Skin Testing in Risk Stratification of Chemotherapy Hypersensitivity. (2020) (3)
- Pioneer: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients with Indolent or Smoldering Systemic Mastocytosis with Symptoms Inadequately Controlled with Standard Therapy (2019) (3)
- Drug Hypersensitivity and Desensitizations. (2017) (3)
- New role for the modern allergist in drug allergy: Assess, diagnose, and de-label. (2018) (3)
- 660 Mast Cell Activation Syndrome- A Newly Recognized Cause of Recurrent Acute Abdominal Pain (2010) (3)
- Reply: To PMID 25017529. (2014) (3)
- Finding the right KIT inhibitor for advanced systemic mastocytosis (2021) (2)
- Patient‐reported outcomes among patients with systemic mastocytosis in routine clinical practice: Results of the TouchStone SM Patient Survey (2022) (2)
- Proceedings of the 2017 WAO Symposium on Hot Topics in Allergy: Pediatric & Regulatory Aspects (2017) (2)
- Capturing Drug-Induced Anaphylaxis Through Electronic Health Records: A Step Forward. (2019) (2)
- Perceptions of patient disease burden and management approaches in systemic mastocytosis: Results of the TouchStone Healthcare Provider Survey (2022) (2)
- Penicillin Allergy. Reply. (2020) (2)
- Prevalence of Allergy and Anaphylaxis in 210 Patients with Mastocytosis. A Study From The Spanish Network on Mastocytosis (REMA) (2007) (2)
- Melphalan desensitization following immediate hypersensitivity in a patient undergoing conditioning for autologous hematopoietic cell transplantation. (2016) (2)
- LAMP1 and CD63 Expression In Mouse Mast Cells and Human Basophils Rendered Hyporesponsive By Antigen/IgE-Mediated Activation and Desensitization (2014) (2)
- Cloning of the gp 49 B Gene of the Immunoglobulin Superfamily and Demonstration That One of Its Two Products Is an Early-expressed Mast Cell Surface Protein Originally Described as gp 49 (2001) (2)
- AllergoOncology: Danger signals in allergology and oncology: A European Academy of Allergy and Clinical Immunology (EAACI) Position Paper (2022) (2)
- Patient Reported Outcomes Among Systemic Mastocytosis (SM) Patients in Routine Clinical Practice: Results from the TouchStone Survey (2020) (2)
- M030 FERRIC CARBOXYMALTOSE DESENSITIZATION IN REFRACTORY IDIOPATHIC IRON-DEFICIENCY ANEMIA, IRON-INFUSION ANAPHYLAXIS, SEVERE ATOPY AND HYPERTRYPTASEMIA (2019) (2)
- Anaphylactic shock to bacitracin irrigation during breast implant surgery. (2019) (2)
- Faculty Opinions recommendation of Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19. (2021) (2)
- [Anaphylaxis and COVID-19 vaccines]. (2021) (2)
- Phosphatases in Mouse Mast Cells Rapid IgE Desensitization: The Role of SHIP-1 (2018) (2)
- Mast cell disorders: A framework of allergy and hematology symptoms leading to personalized treatments. (2021) (2)
- Managing Anaphylaxis in the Office Setting (2016) (2)
- Annals editors on the war in Ukraine. (2022) (2)
- İlaç allerjisinde desensitizasyon (2006) (1)
- Mast Cell Restricted, Tetramer-forming Tryptases Hinder Thrombin-Induced Coagulation of Plasma by Proteolytically Destroying Fibrinogen (2011) (1)
- Drug allergy labeling and delabeling in the coronavirus disease 2019 era (2020) (1)
- Go, ladies, go, the goal is ahead! (2019) (1)
- Basophil Activation Test as a Biomarker for Taxanes Anaphylaxis (2022) (1)
- Clinical presentation and markers of cutaneous versus systemic mastocytosis: the mastocytosis center at brigham and women's hospital in Boston (2015) (1)
- Elevated Tryptase: Conditions and Pitfalls. (2022) (1)
- Cyclical Seminal Plasma Sensitivity in a Woman with Progesterone Autoimmune Dermatitis (2016) (1)
- Endogenous Progesterone Dermatitis: Successful Suppression and Desensitization. (2022) (1)
- Reconsidering anaphylaxis at the time of COVID-19 pandemic. (2020) (1)
- Challenges and safety of beta-lactam desensitization during extracorporeal membrane oxygenation. (2019) (1)
- Outcomes of COVID‐19 vaccination in 323 patients with clonal and non‐clonal mast cell activation disorders (2022) (1)
- A Phase 2/3 Study of BLU-263 in Patients with Indolent Systemic Mastocytosis or Monoclonal Mast Cell Activation Syndrome (2022) (1)
- Challenges in Skin Testing for Progestogen Hypersensitivity. (2020) (1)
- Delayed hypersensitivity reactions to multiple aromatase inhibitors followed by successful desensitization to letrozole. (2021) (1)
- Anaphylaxis: Parts Unknown. (2020) (1)
- Rapid IgE Desensitization Of Mast Cells Impairs Acute And Late-phase Activation Responses And Antigen Internalization (2010) (1)
- Erratum to: Risk and safety requirements for diagnostic and therapeutic procedures in allergology: World Allergy Organization Statement (2017) (1)
- Allergy evaluation and desensitization standards for radiocontrast media. (2020) (1)
- M034 DURVALUMAB DESENSITIZATION DEBACLE DEFINITIVELY DECIPHERED (2019) (1)
- Recurrent neurologic symptoms complicating venom immunotherapy in a patient with systemic mastocytosis and severe Hymenoptera allergy. (2020) (1)
- Network autonomic analysis of post-acute sequelae of COVID-19 and postural tachycardia syndrome (2022) (1)
- Oxaliplatin Induced Immune Thrombocytopenia in Patients with Oxaliplatin Hypersensitivity: Implications for Desensitization (2017) (1)
- Mast Cell Activation Syndromes (2015) (1)
- The Who, What, Where, When, Why, and How of Drug Desensitization. (2022) (1)
- Avapritinib Improved Skin Findings In Patients With Indolent Systemic Mastocytosis (ISM) In the Registrational, Double-Blind, Placebo Controlled PIONEER Study (2023) (0)
- Practical advances in drug hypersensitivity. (2014) (0)
- Clinical Severity Scale of Immediate Hypersensitivity Reactions According to the Modified Ring and Messmer 4-Step Grading Scale (2013) (0)
- Perceptions of Patient Disease Burden and Management Approaches of Systemic Mastocytosis (SM) By Healthcare Providers: Results from the TouchStone SM Survey (2020) (0)
- Successful desensitization in a patient with Von Willebrand´s disease and anaphylaxis to factor VIII/VW (2014) (0)
- A new humanized in vitro model of IgE-mediated rapid desensitization (2014) (0)
- Faculty Opinions recommendation of A novel application of delayed-type hipersensitivity reaction to measure cellular immune response in SARS-CoV-2 exposed individuals. (2021) (0)
- Desensitization induces hyporesponsiveness and cell-surface phenotype changes on mouse mast cells (2014) (0)
- Biologics in Allergic Disease: The Other Side of the Sword (2017) (0)
- Progesterone Autoimmune Dermatitis: Presentation, Diagnosis, Management and Outcomes in 17 Cases (2015) (0)
- Intravenous Iron Hypersensitivity Evaluation and Desensitization (2016) (0)
- Reply to "Penilloate and penicilloate concentrations in practical guidance recommendations". (2021) (0)
- The Mastocytosis Society Mast Cell Activation Syndrome Patient Perceptions Survey: L18 (2019) (0)
- Reactions to Biologicals and Chemotherapy: Mechanisms and Management (2017) (0)
- Chapter 11 – Anaphylaxis (2006) (0)
- Chapter 19 – Chemotherapy Allergy (2018) (0)
- New Challenges and Outcomes for Drug Desensitization (2014) (0)
- Screening for drug-dependent antibodies to prevent complications in patients receiving oxaliplatin desensitization (2022) (0)
- Dual Hypersensitivity To Oxaliplatin Revealed Following Rapid Drug Desensitization: A History Of Anaphylaxis and New-Onset Hemolytic Anemia (2014) (0)
- Efficacy and Safety of Avapritinib in Indolent Systemic Mastocytosis (ISM): Results from the Double Blinded Placebo-Controlled PIONEER Study (2023) (0)
- Elevated Serum Tryptase Levels during Rituximab Hypersensitivity Reaction (2015) (0)
- Humoral biomarkers of latex allergy (2014) (0)
- Multistep IgE Mast Cell Desensitization Is a Dose- and Time-Dependent Process Partially Regulated by SHIP-1. (2023) (0)
- Drug Desensitization in the Covid-19 Pandemic Era: Local Success to Widespread Potential (2021) (0)
- Autoimmune progesterone dermatitis: clinical presentations and management. The Brigham and Women's Hospital experience (2015) (0)
- Mastocytosis (2018) (0)
- The Mastocytosis Society Survey On Mast Cell Disorders: Patient Experiences and Perceptions (2013) (0)
- Mast Cell Activation Syndrome (2018) (0)
- Rapid inpatient and outpatient desensitization for carboplatin or paclitaxel hypersensitivity: A protocol effective in patients with gynecologic malignancies (2005) (0)
- document of the European of and and the Academy of (0)
- Differential mast cell mediators in Systemic Mastocytosis and Hereditary Alpha-tryptasemia. (2022) (0)
- Drug Hypersensitivity and Desensitizations (2017) (0)
- Vaccination-induced Severe Bullous Eruption in a Child with Diffuse Cutaneous Mastocytosis (2012) (0)
- The Importance and the Clinical Impact of Neurologic, Psychiatric, and Other Mediator-Induced Symptoms in Mastocytosis (2018) (0)
- Anaphylaxis (2022) (0)
- Anaphylaxis: watch out, it is everywhere now! (2020) (0)
- Prospective Validation of an Algorithm for the Evaluation and Treatment of Hypersensitivity Reactions to Taxanes, Including Desensitizations (2018) (0)
- Drug Desensitization in the Management of Hypersensitivity Reactions to Monoclonal Antibodies and Chemotherapy (2013) (0)
- Successful desensitization to paclitaxel (Taxol®) in ten patients using a standardized protocol (2003) (0)
- Drug Hypersensitivity and Allergy: From Diagnosis to Treatment (2013) (0)
- Anaphylaxis: Novel Mechanisms and Therapeutic Implications (2013) (0)
- Basophil activation test as a biomarker in allergic patients to platins undergoing rapid desensitization (2015) (0)
- Editorial: The Role of Mast Cells in Immediate Hypersensitivity Reactions (2021) (0)
- Hypo-responsive state of mast cells induced by IgE/antigen desensitisation (2013) (0)
- Anaphylaxis: Data Gaps and Research Needs. (2022) (0)
- Desensitization induces hyporesponsiveness and cell-surface phenotype changes on wild-type and humanized mouse mast cells (2015) (0)
- Deficiency of Interleukin-1 Receptor Antagonist (DIRA): Report of the First Indian Patient and a Novel Deletion Affecting IL1RN (2017) (0)
- Faculty Opinions recommendation of Lineage-specific regulation of inducible and constitutive mast cells in allergic airway inflammation. (2020) (0)
- Anaphylaxis vs. Mastocytosis: A Bone Marrow Biopsy is Always Necessary (2013) (0)
- Elevations in IL-6 Correlate with Cytokine-Related Reactions as a Biomarker for Oxaliplatin Hypersensitivity (2018) (0)
- In Person. (2013) (0)
- Drug desensitization in the coronavirus disease 2019 pandemic era (2021) (0)
- List of Contributors (2019) (0)
- Anaphylactic and anaphylactoid reactions to chemotherapy: outcomes and safety of rapid intravenous and intraperitoneal desensitizations in 413 cases (2008) (0)
- Life-long learning and the American Board of Allergy and Immunology: Practice improvement comes of age. (2019) (0)
- Comprar Anaphylaxis And Hypersensitivity Reactions | M. C. Castells | 9781603279505 | Humana Press (2010) (0)
- Faculty Opinions recommendation of The anti-IgE mAb omalizumab induces adverse reactions by engaging Fcγ receptors. (2020) (0)
- Fundamentals of Desensitization Indications and Risk Stratification: Lessons from the Brigham and Women's Hospital Desensitization Center (2018) (0)
- Mast Cell Activation Syndromes: Anaphylaxis and Mastocytosis in the 21st Century (2013) (0)
- Infusion Reactions from Monoclonal Antibodies and the Role for Challenge and Desensitization (2015) (0)
- Drug Challenge vs. Desensitization (2017) (0)
- Oupatient Lenalidomide Desensitization For Delayed Hypersensitivity Reactions In 5 Patients With Multiple Myeloma (2014) (0)
- Elevated tryptase levels in food-induced anaphylactic reactions (2002) (0)
- Successful Implementation of a Standardized Rapid Drug Desensitization Protocol for Chemotherapy and Rituximab in 413 Cases (2008) (0)
- Qualitative Research to Understand the Patient Experience in Non-Advanced Systemic Mastocytosis (2023) (0)
- Faculty Opinions recommendation of Shared B cell memory to coronaviruses and other pathogens varies in human age groups and tissues. (0)
- QIM23-142: Evaluation of a Standardized Approach to Hypersensitivity/Infusion Reaction Management in a Large Ambulatory Oncology Center (2023) (0)
- Differential outcomes of 609 rapid drug desensitization (RDD) for type I hypersensitivity to platins and taxanes (2014) (0)
- Utilizing Biologics in Drug Desensitization (2022) (0)
- Anaphylaxis after Hymenoptera Sting-Overlap with Mast Cell Disorder (2016) (0)
- Evaluation and diagnosis of mastocytosis (cutaneous and systemic) (2014) (0)
- Drug allergy biomarkers Are we there yet? (2023) (0)
- Nanoallergen Platform for the Detection of Platin Drugs Allergies (2019) (0)
- Book Review (2022) (0)
- Women in science and medicine (2021) (0)
- Avapritinib Improved Symptoms and Quality of Life in Patients With Indolent Systemic Mastocytosis in the PIONEER Study (2023) (0)
- Invited Commentary: Mast Cell Activation (2017) (0)
- Faculty Opinions recommendation of Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody Production. (0)
- The Mastocytosis Society Survey on Mast Cell Disorders: Part 2-Clinical Experiences, Co-Morbidities and Additional Concerns (2015) (0)
- Vaccination: Just do it! (2022) (0)
- Phenotypic Expression of Hypersensitivity Drug Reactions in Outpatient Infusion Centers, 1 Year Experience (2018) (0)
- Improving Allergy and Immunology Education For The Internal Medicine Resident Through Internet-Based Learning Modules (2014) (0)
- Mast cell-derived htryptase-beta functions as a potent anticoagulant by proteolytically damaging fibrinogen. (2014) (0)
- Drug Allergy and Perioperative Management of Mastocytosis (2019) (0)
- Basophil activation test in allergic patients to platins undergoing rapid desensitization (2014) (0)
- AllergoOncology: Is ultra-low IgE a potential novel biomarker in cancer? A position paper of the European Academy of Allergy and Clinical Immunology (EAACI) (2020) (0)
This paper list is powered by the following services:
Other Resources About Mariana Castells
What Schools Are Affiliated With Mariana Castells?
Mariana Castells is affiliated with the following schools:
